Jul 17, 2006 - Fludarabine-based combination chemotherapy regimens are highly effective in the treatment of patients with indolent lymphoproliferative.
773
The Influence of Increasing Age on the Deliverability and Toxicity of Fludarabine-Based Combination Chemotherapy Regimens in Patients With Indolent Lymphoproliferative Disorders Mark N. Polizzotto, MB, BS, BMedSci1 Constantine S. Tam, MB, BS1 Alvin Milner, BSc, PhD2 E. Henry Januszewicz, MB, BS3 H. Miles Prince, MB, BS, MD3 David Westerman, MB, BS3 Max M. Wolf, MB, BS3 John F. Seymour, MB, BS3 1
Department of Hematology, The Alfred Hospital, Melbourne, Victoria, Australia. 2
Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 3
Department of Hematology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.
BACKGROUND. Fludarabine-based combination chemotherapy regimens are highly effective in the treatment of patients with indolent lymphoproliferative disorders. Despite the prevalence of such disorders in older patients, the effect of increasing age on the deliverability of these regimes has not been assessed.
METHODS. The authors analyzed the effect of increasing age on the deliverability and toxicity of 3 fludarabine-based regimens, all using fludarabine 25 mg/m2 per day for 3 days intravenously every 28 days, in 180 patients who were stratified into 2 age groups (age
